VTGN VistaGen Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VTGN

Price (delayed)

$0.2264

Market cap

$9.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

-$20.46M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 22

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and ...

Highlights
The gross profit has soared by 161% YoY and by 61% from the previous quarter
VistaGen Therapeutics's revenue has surged by 161% YoY and by 61% QoQ
VistaGen Therapeutics's EPS has decreased by 10% YoY but it has increased by 3.7% from the previous quarter
The equity has decreased by 50% YoY and by 30% QoQ
VTGN's quick ratio is down by 44% year-on-year and by 22% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vistagen.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VTGN

VTGN stock price

How has the VistaGen Therapeutics stock price performed over time
Intraday
0.18%
1 week
-1.22%
1 month
-65.94%
1 year
-91.65%
YTD
-65.8%
QTD
0.18%

Financial performance

How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$1.27M
Gross profit
$1.27M
Operating income
-$72.13M
Net income
-$69.69M
Gross margin
100%
Net margin
-5,491.3%
The gross profit has soared by 161% YoY and by 61% from the previous quarter
VistaGen Therapeutics's revenue has surged by 161% YoY and by 61% QoQ
The operating margin has soared by 51% year-on-year and by 36% since the previous quarter
The company's net margin rose by 48% YoY and by 35% QoQ

Price vs fundamentals

How does VTGN's price correlate with its fundamentals

Growth

What is VistaGen Therapeutics's growth rate over time

Valuation

What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.25
P/S
6.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-16.12
VistaGen Therapeutics's EPS has decreased by 10% YoY but it has increased by 3.7% from the previous quarter
The price to book (P/B) is 88% lower than the 5-year quarterly average of 2.0 and 75% lower than the last 4 quarters average of 1.0
The equity has decreased by 50% YoY and by 30% QoQ
VistaGen Therapeutics's revenue has surged by 161% YoY and by 61% QoQ
The price to sales (P/S) is 92% lower than the last 4 quarters average of 81.8

Efficiency

How efficient is VistaGen Therapeutics business performance
The ROE has plunged by 126% YoY and by 21% from the previous quarter
The company's return on assets has shrunk by 102% YoY and by 18% QoQ
The company's return on invested capital has shrunk by 62% YoY and by 4.2% QoQ
VistaGen Therapeutics's ROS has increased by 48% YoY and by 35% from the previous quarter

Dividends

What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VTGN.

Financial health

How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio is down by 44% year-on-year and by 22% since the previous quarter
The current ratio has decreased by 44% YoY and by 21% from the previous quarter
The company's debt is 97% lower than its equity
The equity has decreased by 50% YoY and by 30% QoQ
VTGN's debt to equity has surged by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.